AIM Vaccine Co., Ltd. Class H ( (HK:6660) ) has issued an update.
AIM Vaccine Co., Ltd. has submitted an application for clinical trials of its mRNA shingles/herpes zoster vaccine to the National Medical Products Administration of China. Preclinical results indicate that the vaccine shows significantly higher T-cell immunity and antibody titers compared to existing vaccines, highlighting its potential effectiveness and safety. With no mRNA vaccines for shingles currently approved globally, the market presents a substantial growth opportunity, projected to reach $23.9 billion by 2030. The company’s established quality management and production systems position it well for rapid industrialization and commercialization upon approval.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a joint stock company incorporated in China, focusing on the development and commercialization of vaccine products. The company utilizes an mRNA technology platform to advance its vaccine pipeline, emphasizing innovation in the field of vaccines, specifically targeting diseases like shingles and herpes zoster.
YTD Price Performance: -5.05%
Average Trading Volume: 3,360,662
Technical Sentiment Consensus Rating: Buy
For a thorough assessment of 6660 stock, go to TipRanks’ Stock Analysis page.